SCHEMBL6776516

SCHEMBL6776516

NC(CC(=O)O)c1occ2ccccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.41
CYP2C19 P33261 2/20 0.41
CYP2C9 P11712 1/20 0.41
HTT P42858 1/20 0.41
KMT2A Q03164 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM4E B2RXH2 3/20 0.38
SLC1A3 P43003 2/20 0.37
SLC1A2 P43004 2/20 0.37
SLC1A1 P43005 2/20 0.37
TDP1 Q9NUW8 2/20 0.37
GABBR2 O75899 1/20 0.37
GABBR1 Q9UBS5 1/20 0.37
MEN1 O00255 1/20 0.35
MIF P14174 1/20 0.35
CASP1 P29466 1/20 0.34
ALDH1A1 P00352 2/20 0.34
GLA P06280 1/20 0.34
GAA P10253 1/20 0.34
HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL27469220 0.98 HPGD (0.40) HPGDCYP2C19CYP2C9HTTKMT2A
SCHEMBL10919731 0.80 KDM4E (0.36) HPGDCYP2C19KMT2AKDM4ESLC1A3
SCHEMBL3983275 0.77 HTR2A (0.32)
SCHEMBL27480509 0.74 S1PR2 (0.41) HPGDCYP2C19CYP2C9HTTKMT2A
SCHEMBL27724947 0.73 MAOB (0.45) HPGDCYP2C19CYP2C9HTTKDM4E
SCHEMBL1520324 0.72 HPGD (0.59) HPGDCYP2C19CYP2C9HTTKMT2A
SCHEMBL5720984 0.72 HPGD (0.59) HPGDCYP2C19CYP2C9HTTKMT2A
SCHEMBL29666532 0.72 HPGD (0.59) HPGDCYP2C19CYP2C9HTTKMT2A
SCHEMBL16541031 0.72 HPGD (0.59) HPGDCYP2C19CYP2C9HTTKMT2A
SCHEMBL11195352 0.72 AKR1B1 (0.44) HPGDCYP2C19CYP2C9SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed